Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients

Jun 27, 2024

Optime Care, an AscellaHealth company, is thrilled to announce a new partnership with Rigel Pharmaceuticals. Together, we will be supporting patients using GAVRETO®, a groundbreaking targeted therapy for cancers caused by abnormal RET genes. GAVRETO® is taken orally once daily, making it a convenient and effective treatment option.

See all Member News